OBJECTIVE: To assess health values in subjects with systemic sclerosis (SSc) and determine variability explained by demographics, clinical factors, health status, and disease severity. METHODS: We interviewed 107 individuals with SSc who attended national and local Scleroderma Foundation meetings in 2005. Health status was measured using the Short Form 36 (SF-36) Physical Component Summary (PCS; range 0-100) and Mental Component Summary (MCS; range 0-100), the Center for Epidemiologic Studies Depression Scale (CES-D; range 0-60), and the Health Assessment Questionnaire (HAQ) disability index (DI; range 0-3). Disease severity was assessed using a visual analog scale (VAS; range 0-150). Health value measures included the 0-100 health rating scale (RS), standard gamble (SG; range 0.0-1.0), and time trade-off (TTO; range 0.0-1.0). We performed univariate analyses to compare scores between participants with limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc), and multivariable analyses for 3 outcome measures: RS, SG, and TTO, controlling for demographics, type of SSc, health status, and disease severity. RESULTS: Of the 107 participants, 48 had dcSSc and 59 had lcSSc. Ninety-seven were women and 83 were white. The median scores for the PCS, MCS, and HAQ DI were 36.9, 45.5, and 0.9, respectively. Fifty-five subjects had significant depressive symptoms (CES-D score >or=16). The median RS, SG, and TTO scores were 62, 0.83 (indicating a willingness to accept up to a 17% risk of immediate death in exchange for perfect health), and 0.88 (indicating a willingness to give up a median of 12% of life expectancy in exchange for perfect health), respectively. Subjects with dcSSc had lower RS scores but higher SG scores (corresponding to a willingness to accept only a smaller risk of death) than subjects with lcSSc. TTO scores were similar in the 2 groups. Health values were variably related to factors such as demographics, VAS score, disease classification, and SF-36 PCS and MCS scores (R(2) = 0.22, 0.23, and 0.66 for the SG, TTO, and RS models, respectively). CONCLUSION: Individuals with dcSSc have lower health ratings but higher SG health values than individuals with lcSSc. These findings have implications for decision analysis and cost-effectiveness analysis.
OBJECTIVE: To assess health values in subjects with systemic sclerosis (SSc) and determine variability explained by demographics, clinical factors, health status, and disease severity. METHODS: We interviewed 107 individuals with SSc who attended national and local Scleroderma Foundation meetings in 2005. Health status was measured using the Short Form 36 (SF-36) Physical Component Summary (PCS; range 0-100) and Mental Component Summary (MCS; range 0-100), the Center for Epidemiologic Studies Depression Scale (CES-D; range 0-60), and the Health Assessment Questionnaire (HAQ) disability index (DI; range 0-3). Disease severity was assessed using a visual analog scale (VAS; range 0-150). Health value measures included the 0-100 health rating scale (RS), standard gamble (SG; range 0.0-1.0), and time trade-off (TTO; range 0.0-1.0). We performed univariate analyses to compare scores between participants with limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc), and multivariable analyses for 3 outcome measures: RS, SG, and TTO, controlling for demographics, type of SSc, health status, and disease severity. RESULTS: Of the 107 participants, 48 had dcSSc and 59 had lcSSc. Ninety-seven were women and 83 were white. The median scores for the PCS, MCS, and HAQ DI were 36.9, 45.5, and 0.9, respectively. Fifty-five subjects had significant depressive symptoms (CES-D score >or=16). The median RS, SG, and TTO scores were 62, 0.83 (indicating a willingness to accept up to a 17% risk of immediate death in exchange for perfect health), and 0.88 (indicating a willingness to give up a median of 12% of life expectancy in exchange for perfect health), respectively. Subjects with dcSSc had lower RS scores but higher SG scores (corresponding to a willingness to accept only a smaller risk of death) than subjects with lcSSc. TTO scores were similar in the 2 groups. Health values were variably related to factors such as demographics, VAS score, disease classification, and SF-36 PCS and MCS scores (R(2) = 0.22, 0.23, and 0.66 for the SG, TTO, and RS models, respectively). CONCLUSION: Individuals with dcSSc have lower health ratings but higher SG health values than individuals with lcSSc. These findings have implications for decision analysis and cost-effectiveness analysis.
Authors: Roozbeh Sharif; Maureen D Mayes; Perry M Nicassio; Emilio B Gonzalez; Hilda Draeger; Terry A McNearney; Rosa M Estrada-Y-Martin; Deepthi K Nair; John D Reveille; Frank C Arnett; Shervin Assassi Journal: Semin Arthritis Rheum Date: 2011-03-22 Impact factor: 5.532
Authors: Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays Journal: Qual Life Res Date: 2007-04-03 Impact factor: 4.147
Authors: D Khanna; D J Lovell; E Giannini; P J Clements; P A Merkel; J R Seibold; M Matucci-Cerinic; C P Denton; M D Mayes; V D Steen; J Varga; D E Furst Journal: Ann Rheum Dis Date: 2007-09-24 Impact factor: 19.103
Authors: Thais F Marighela; Patrícia de S Genaro; Marcelo M Pinheiro; Vera L Szejnfeld; Cristiane Kayser Journal: Clin Rheumatol Date: 2013-04-03 Impact factor: 2.980
Authors: Leticia Leon; Lydia Abasolo; Marta Redondo; Miguel Angel Perez-Nieto; Luis Rodriguez-Rodriguez; Maria Isabel Casado; Rafael Curbelo; Juan Angel Jover Journal: Rheumatol Int Date: 2013-09-27 Impact factor: 2.631
Authors: Vijay Bodukam; Ron D Hays; Paul Maranian; Daniel E Furst; James R Seibold; Ann Impens; Maureen D Mayes; Philip J Clements; Dinesh Khanna Journal: Rheumatology (Oxford) Date: 2010-09-30 Impact factor: 7.580
Authors: B D Thombs; M Bassel; L McGuire; M T Smith; M Hudson; J A Haythornthwaite Journal: Rheumatology (Oxford) Date: 2008-08-13 Impact factor: 7.580
Authors: Chiara M Antonioli; Giovanni Bua; Anna Frigè; Katia Prandini; Sara Radici; Mirko Scarsi; Elisabetta Danieli; Andrea Malvicini; Paolo Airo Journal: Clin Rheumatol Date: 2008-09-16 Impact factor: 2.980
Authors: Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Panos Kanavos; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Márta Péntek; Claudia Delgado; Johann Mathias von der Schulenburg; Ulf Persson; Karine Chevreul; Giovanni Fattore Journal: Eur J Health Econ Date: 2016-04-02